Skip to Main Content

News & Views

Latest Updates

Volastra Therapeutics Expands Leadership Team to Tackle Cancer

November 16, 2021

Company brings in experienced biopharma leaders to head translational, data science and business development functions...

Volastra Therapeutics Co-founder Samuel Bakhoum to Deliver Plenary Presentation at American Association for Cancer Research Annual Meeting 2021

Dr. Bakhoum will present on the critical role of chromosomal instability in cancer metastasis. NEW...

Volastra Therapeutics Extends Seed Financing to $44 Million to Advance Drug Discovery Programs to Prevent Cancer Metastasis

Company founded by Polaris Partners with latest financing led by Vida Ventures Funding will support...

Our Perspectives

Getting to Know Scott Drutman, M.D., Ph.D., SVP, Head of Translational Science

November 8, 2021

Welcome to Scott Drutman, M.D., Ph.D., who recently joined Volastra as Senior Vice President, Head...

Charting Volastra’s R&D path

October 4, 2021

By Michael Arensman, Aaron Phillips and Hyeseok Shim Every medicine starts with a discovery. But...

Getting to know Rachel Zolot Schwartz, VP, Business Development & Commercial

Welcome to Rachel Zolot Schwartz, who recently joined Volastra as Vice President, Business Development &...

In The News

Researchers see a ‘tractable approach’ to taming cancer metastasis

Volastra, Microsoft team up to battle cancer

Wall Street Journal

With fresh investor cash in hand, Volastra partners with Microsoft to develop metastatic cancer biomarker platform

Contact Us

Volastra
1361 Amsterdam Ave Suite 520
New York, NY 10027
Phone: (646) 344-1248
contactus@volastratx.com

Media Contact
Wendy Ryan
Ten Bridge Communications
(781) 316-4424
wendy@tenbridgecommunications.com